姓名：李琴 性别：女 职称：主任医师、副教授 招生院所：附属友谊医院 招生类型：科学与专业学位(硕) 招生专业：肿瘤学(硕) 研究方向名称：肿瘤靶向药物耐药机制及新型靶向药物的转化研究 电子信箱：qinli128003@163.com


社会任职
1. 《中华内分泌外科杂志》通讯编委
2. 《中华实验和临床病毒学杂志》通讯编委
3. 北京肿瘤防治研究会中医分委会 委员
4. 北京肿瘤防治研究会乳腺癌分委会 委员
5. 北京癌症防治学会乳腺癌精准靶向诊疗专业委员会
6. 北京癌症防治协会消化道肿瘤精准治疗专业委员会 常务委员
个人简历
1. 200109-200407:首都医科大学 博士研究生
2. 201301-201812:北京友谊医院 副主任医师
3. 201609-201709:美国MD Anderson Cancer Center Visiting Scientist
4. 201901-:北京友谊医院 主任医师
重要学术论文
1. Yingrui Li,Kang Dong, Xueke Fan, Jun Xie, Miao Wang, Songtao Fu*, Qin Li*.DNT cell-based immunotherapy: progress and applications. Journal of Cancer. 2020,11(13):3717-3724.SCI
2. Yongfu Li, Yuhan Wei, Wenjun Tang, Jingru Luo, Minghua Wang, Haifeng Lin, Hong Guo, Yuling Ma, Jun Zhang, Qin Li*. Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer. PeerJ. 2020,e8067:1-10.SCI
3. Du Q, Che J, Jiang X, Li L, Luo X, Li Q*.PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Clin Breast Cancer. 2020,20(1):e99-e111.SCI
4. Wei Y, Du Q, Jiang X, Li L, Li T, Li M, Fan X, Li Y, Kariminia S, Li Q*. Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis . Crit Rev Oncol Hematol. 2019,138:178-189.SCI
5. Jiang X, Li L, Li Y, Li Q*.Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. Journal of Cancer. 2019,10(7):1764-1771.SCI
6. Zhao P, Li L, Jiang X, Li Q*.Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019,12(1):54.SCI
7. Yang L, Jiang X, Yan H, Li Y, Zhen H, Chang B, Kariminia S, Li Q*..Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018,18(1):1-9.SCI
8. Li Q, Li L, Jiang X, Du Q, Li Y, Li T, Gong H, Cao B..Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis. BMJ Open. 2018,8(11):1-8.SCI
9. Li L, Zhang J, Jiang X, Li Q*..Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018,8(10):1947-1956.SCI
10. Li L, Chang B, Jiang X, Fan X, Li Y, Li T, Wu S, Zhang J, Kariminia S, Li Q*..Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. 2018,18(1):1-10.SCI
11. Yang L, Li Y, Shen E, Cao F, Li L, Li X, Wang X, Kariminia S, Chang B, Li H, Li Q*..NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. Int J Oncol. 2017,51(5):1553-1562.SCI
12. Qin Li, RuiXue Zhang, Han Yan, Pengfei Zhao, Li Wu, Hui Wang, Teng Li, Bangwei Cao..Prognostic significance of HER3 in patients with malignant solid tumors . Oncotarget. 2017,8(40):1-12.SCI
13. Li Z#, Li Q#, Wu J, Wang M, Yu J..Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do. Molecules. 2016,21(10):1331.SCI
14. Qin Li, Lei Zhang, XiuHong Li, Han Yan, Liuting Yang, Yingying Li, Teng Li, Jing Wang and Bangwei Cao..The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer. 2016,16(1):910.SCI
15. 李琴, 赵鹏飞, 庞慧, 曹邦伟..NCCN指南在肿瘤学临床教学过程中的应用及临床价值. 中国高等医学教育. 2015,9:67-69.核心期刊
16. Li Q, Yan H, Zhao P, Yang Y, Cao B..Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Scientific Reports. 2015,5:15746.SCI
17. Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao..Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One. 2014,9(8):e104346.SCI
18. Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao..Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Clinical Therapeutics. 2014,36(7):1054-1063.SCI
19. 李琴, 闫涵, 赵鹏飞, 张瑞雪, 原振龑, 曹邦伟..吉西他滨联合铂类与吉西他滨单药治疗晚期胰腺癌疗效的系统比较. 临床与实验医学杂志. 2014,13(16):1317-1321.核心期刊
20. 李琴, 沈恩允, 王明群, 赵鹏飞, 原振龑, 曹邦伟..新型HER3单克隆抗体逆转胃癌HER2过表达N87细胞Lapatinib耐药的研究. 临床与实验医学杂志. 2014,13(15):1225-1228.核心期刊
21. 李琴, 赵鹏飞, 袁振龑, 曹邦伟..肿瘤内科临床教学过程中医学生循证医学思维的培养. 中国高等医学教育. 2014,8:103-104.核心期刊
22. 李琴, 车娟娟, 李卉惠, 闫涵, 曹邦伟..案例教学法在肿瘤内科临床轮转医师教学中的应用与分析. 中国高等医学教育. 2013,6:104-105.核心期刊
23. Qin Li, Zhenyan Yuan, Bangwei Cao..The function of human epidermal growth factor receptor-3 and its role in tumors (Review). Oncology Reports. 2013,30(6):2563-2570.SCI
24. Liu W, Zheng J, Li Q*..Application of imaging modalities for evaluating neuroblastoma. J Pediatr Endocrinol Metab. 2013,26(11-12):1015-1120.SCI
25. Li Q, Yang J..Role of imaging methods in metastatic melanoma. Onkologie. 2012,35(9):522-526.SCI
26. 李琴, 甄洪超, 李卉惠, 朱圣韬, 王婧, 李坤, 徐昌青, 曹邦伟..TBX-21基因启动子区多态性与食管鳞癌易感、临床病理特征的相关性研究. 临床肿瘤学杂志. 2011,16(6):487-491.核心期刊
27. 李琴, 王婧, 李卉惠, 苏强, 马颖杰, 赵志海 曹邦伟..前列腺特异性抗原、病理分级与前列腺癌骨转移的关系探讨. 临床荟萃. 2011,26(3):228-230.核心期刊
28. 李琴, 苏强, 王婧, 李卉惠, 马颖杰, 赵志海, 钱林学, 曹邦伟, 贾继东, 王宝恩..无创评估肝硬化患者食管和（或）胃底静脉曲张因素的分析. 首都医科大学学报. 2011,32(3):426-430.核心期刊
29. 李琴, 曹邦伟, 郝瑞瑞, 苏强, 李卉慧, 王婧, 马颖杰..氟代脱氧葡萄糖联合线路单光子发射计算机断层显像在肺癌诊断中的价值. 山西医药杂志. 2010,10(39):939-940.核心期刊
主编或副主编的著作/译著
重要奖项